clinical trial · NCT07047885
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
H. Lee Moffitt Cancer Center and Research Institute·phase1·recruiting·n = 38
Cutaneous T Cell LymphomaRopeginterferon alfa-2b
brief summary
This is a single-center, phase I/IB study to identify the recommended phase II dose of Ropeginterferon-alfa 2b (P1101) in patients with CTCL who have failed at least two prior lines of skin-directed therapy (Stage IA-IB) or have less than a complete response to phototherapy or extracorporeal photopheresis (ECP) or total skin electron beam therapy (TSET), or stable/progressive disease after at least two lines of topical therapy (Stage IIA-IIIB).
started
Aug 27, 2025
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Apr 1, 2026
official title
A Phase I/IB Study of Ropeginterferon in Patients With Cutaneous T-Cell Lymphoma (CTCL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol